Hoth Therapeutics’ (HOTH) Buy Rating Reiterated at D. Boral Capital

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $5.00 target price on the stock. D. Boral Capital’s target price suggests a potential upside of 385.44% from the stock’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Hoth Therapeutics in a research report on Thursday, January 23rd.

Hoth Therapeutics Trading Down 5.5 %

Shares of NASDAQ:HOTH traded down $0.06 during trading on Monday, hitting $1.03. 313,695 shares of the company were exchanged, compared to its average volume of 3,505,996. The stock has a market cap of $7.11 million, a price-to-earnings ratio of -0.78 and a beta of 0.84. Hoth Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $3.80. The firm has a fifty day moving average price of $1.22 and a two-hundred day moving average price of $0.99.

Institutional Trading of Hoth Therapeutics

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC bought a new position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.47% of Hoth Therapeutics at the end of the most recent quarter. Institutional investors own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.